Wealth Enhancement Advisory Services LLC Has $560,000 Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Wealth Enhancement Advisory Services LLC reduced its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 10.0% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 4,481 shares of the biotechnology company’s stock after selling 500 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Sarepta Therapeutics were worth $560,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in SRPT. Riggs Asset Managment Co. Inc. raised its holdings in Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 75 shares in the last quarter. EP Wealth Advisors LLC raised its stake in Sarepta Therapeutics by 2.1% in the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock valued at $774,000 after purchasing an additional 103 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in Sarepta Therapeutics by 1.9% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock valued at $1,000,000 after purchasing an additional 120 shares in the last quarter. Innealta Capital LLC bought a new stake in Sarepta Therapeutics during the second quarter worth about $31,000. Finally, UMB Bank n.a. grew its stake in Sarepta Therapeutics by 105.9% during the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock worth $48,000 after buying an additional 197 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Transactions at Sarepta Therapeutics

In other news, Director Michael Andrew Chambers purchased 37,038 shares of the business’s stock in a transaction on Friday, August 16th. The shares were acquired at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the transaction, the director now owns 284,034 shares of the company’s stock, valued at $38,003,749.20. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Michael Andrew Chambers bought 37,038 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The shares were bought at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the transaction, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 7.70% of the company’s stock.

Wall Street Analyst Weigh In

SRPT has been the subject of several analyst reports. Citigroup dropped their target price on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Guggenheim boosted their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday. Needham & Company LLC reaffirmed a “buy” rating and issued a $205.00 target price on shares of Sarepta Therapeutics in a report on Thursday. Barclays lowered their price target on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 21st. One analyst has rated the stock with a hold rating, twenty have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $181.33.

Sarepta Therapeutics Trading Down 5.9 %

NASDAQ SRPT opened at $120.42 on Friday. The firm has a market capitalization of $11.48 billion, a PE ratio of 267.61 and a beta of 0.81. The business’s 50-day moving average price is $126.20 and its two-hundred day moving average price is $132.77. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. Sarepta Therapeutics, Inc. has a 12 month low of $75.85 and a 12 month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The business had revenue of $362.90 million for the quarter, compared to analysts’ expectations of $394.38 million. During the same period in the prior year, the business posted ($0.27) earnings per share. The firm’s revenue was up 38.9% on a year-over-year basis. On average, analysts expect that Sarepta Therapeutics, Inc. will post 1.48 EPS for the current year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.